![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CENPBD1 |
Gene summary for CENPBD1 |
![]() |
Gene information | Species | Human | Gene symbol | CENPBD1 | Gene ID | 92806 |
Gene name | CENPB DNA-binding domain containing 1, pseudogene | |
Gene Alias | CENPBD1 | |
Cytomap | 16q24.3 | |
Gene Type | pseudo | GO ID | GO:0005575 | UniProtAcc | B2RD01 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
92806 | CENPBD1 | HCC1_Meng | Human | Liver | HCC | 6.23e-15 | 1.43e-02 | 0.0246 |
92806 | CENPBD1 | HCC2_Meng | Human | Liver | HCC | 1.78e-03 | 2.98e-03 | 0.0107 |
92806 | CENPBD1 | HCC1 | Human | Liver | HCC | 8.04e-14 | 3.21e+00 | 0.5336 |
92806 | CENPBD1 | HCC2 | Human | Liver | HCC | 1.35e-18 | 3.19e+00 | 0.5341 |
92806 | CENPBD1 | HCC5 | Human | Liver | HCC | 3.91e-08 | 1.15e+00 | 0.4932 |
92806 | CENPBD1 | S014 | Human | Liver | HCC | 2.76e-07 | 3.03e-01 | 0.2254 |
92806 | CENPBD1 | S015 | Human | Liver | HCC | 2.82e-06 | 3.86e-01 | 0.2375 |
92806 | CENPBD1 | S016 | Human | Liver | HCC | 6.61e-05 | 2.63e-01 | 0.2243 |
92806 | CENPBD1 | S028 | Human | Liver | HCC | 3.96e-02 | 2.00e-01 | 0.2503 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | ![]() |
Oral cavity | LP | ![]() |
Oral cavity | EOLP | ![]() |
Oral cavity | NEOLP | ![]() |
Esophagus | HGIN | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CENPBD1 | SNV | Missense_Mutation | rs770905097 | c.296N>G | p.Glu99Gly | p.E99G | B2RD01 | protein_coding | deleterious(0.01) | possibly_damaging(0.835) | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
CENPBD1 | SNV | Missense_Mutation | rs770905097 | c.296A>G | p.Glu99Gly | p.E99G | B2RD01 | protein_coding | deleterious(0.01) | possibly_damaging(0.835) | TCGA-A2-A0ET-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
CENPBD1 | SNV | Missense_Mutation | rs770905097 | c.296A>G | p.Glu99Gly | p.E99G | B2RD01 | protein_coding | deleterious(0.01) | possibly_damaging(0.835) | TCGA-A2-A1G0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
CENPBD1 | SNV | Missense_Mutation | rs770905097 | c.296A>G | p.Glu99Gly | p.E99G | B2RD01 | protein_coding | deleterious(0.01) | possibly_damaging(0.835) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
CENPBD1 | SNV | Missense_Mutation | rs770905097 | c.296N>G | p.Glu99Gly | p.E99G | B2RD01 | protein_coding | deleterious(0.01) | possibly_damaging(0.835) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CENPBD1 | SNV | Missense_Mutation | novel | c.176N>C | p.Asp59Ala | p.D59A | B2RD01 | protein_coding | tolerated(0.95) | possibly_damaging(0.754) | TCGA-AO-A0JJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophospamide | SD |
CENPBD1 | SNV | Missense_Mutation | novel | c.246N>A | p.His82Gln | p.H82Q | B2RD01 | protein_coding | tolerated(0.59) | benign(0.003) | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
CENPBD1 | SNV | Missense_Mutation | rs770905097 | c.296N>G | p.Glu99Gly | p.E99G | B2RD01 | protein_coding | deleterious(0.01) | possibly_damaging(0.835) | TCGA-B6-A1KF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CENPBD1 | SNV | Missense_Mutation | rs770905097 | c.296N>G | p.Glu99Gly | p.E99G | B2RD01 | protein_coding | deleterious(0.01) | possibly_damaging(0.835) | TCGA-BH-A0B5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR |
CENPBD1 | SNV | Missense_Mutation | c.10N>A | p.Glu4Lys | p.E4K | B2RD01 | protein_coding | tolerated(1) | benign(0) | TCGA-BH-A1F5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |